The Safety and Efficacy of NouvSoma001 in Ischemic Stroke
NCT06612710 is a phase 1 interventional trial sponsored by Wei Wang. As of 18 Nov 2026, it is recruiting participants. It studies A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection in Ischemic Stroke. The registry lists an enrollment of 69 participants at 1 site in 1 country. The registry lists a start date of 30 Nov 2025 and a primary completion date of 30 Dec 2026. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06612710 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Wei Wang |
| Enrollment | 69 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Ischemic Stroke |
| Drugs | A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection |
| Start | 30 Nov 2025 |
| Primary completion | 30 Dec 2026 |
| Study completion | 30 Nov 2027 |
| Last update posted | 21 Jan 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Chuan Qin, MD
Tongji Hospital
Principal Investigator - Daishi Tian, MD
Tongji Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tongji Hospital Affiliated To Tongji Medical College of Huazhong University Ofscience and Technology
Wuhan, Hubei
Recruiting
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06612710
Each answer restates registry values shown on this page.
What is NCT06612710?
NCT06612710 is a phase 1 interventional trial sponsored by Wei Wang. It studies A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection in Ischemic Stroke.
Is NCT06612710 recruiting?
As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT06612710?
The registry names Chuan Qin, MD (principal investigator, Tongji Hospital), Daishi Tian, MD (principal investigator, Tongji Hospital) and Wei Wang, MD (principal investigator, Tongji Hospital) as overall officials.
Where does NCT06612710 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.
Which drugs does NCT06612710 study?
The registered drug and biological interventions are A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection.
When is NCT06612710 expected to complete?
The registry lists a primary completion date of 30 Dec 2026 and a study completion date of 30 Nov 2027. The sponsor last updated the record on 21 Jan 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.